Runda Medical boosts 2025 related-party transaction estimates

Shanghai Runda Medical Technology Co., Ltd. announced an increase in its estimated routine related-party transactions for 2025, driven by business development needs. The total estimated transactions are projected to rise from RMB46,700.00 to RMB54,200.00, an increase of RMB7,500.00. This adjustment follows approvals from the company's fifth board of directors, with related parties abstaining from voting.

Key changes include an increase in purchases from Yunnan Serres Bio-Tech Co., Ltd. from RMB1,700.00 to RMB2,000.00, an increase of RMB300.00, attributed to new product demand. Sales to Guorun Medical Supply Chain Services (Shanghai) Co., Ltd. are expected to rise from RMB45,000.00 to RMB52,200.00, an increase of RMB7,200.00, reflecting general business operations.

These related-party transactions are deemed necessary for the company's normal operations, ensuring stable business development. The transactions are conducted on a fair and arm's-length basis, with pricing guided by market principles.